Regulation & Policy (Pharma & Healthcare)


Publication Single User License (PDF) Price
Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Date Published: Dec 1 2015

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2015 in Pharmaceuticals

Summary

$1,000.00
Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2015

Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2015

Date Published: Nov 16 2015
Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2015 report discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. 
 
$1,450.00
Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015

Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015

Date Published: Nov 16 2015
Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015 report depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies. 
$2,250.00
Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals

Date Published: Nov 4 2015

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals

Summary

$1,000.00
Carfilzomib  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Carfilzomib - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Carfilzomib  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of relapsed multiple myeloma optionally in combination with Lenalidomide and/or Dexamethasone Onyx Pharm (Kyprolis)
 

Report Summary

$1,400.00
Deferiprone  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Deferiprone - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Deferiprone  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of transfusional iron overload due to thalassemia syndromes Orphan (Ferriprox); Apotex (Ferriprox); Apopharma (Ferriprox)
 

Report Summary

$1,400.00
Eluxadoline  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Eluxadoline - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Eluxadoline  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of irritable bowel syndrome with diarrhea Forest Tosara (Viberzi)
 

Report Summary

$1,400.00
Evolocumab  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Evolocumab - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Evolocumab  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of homozygous familial hypercholesterolaemia in combination with lipid-lowering therapies; Treatment of primary hypercholesterolaemia (heterozygous familial and non-familial), or mixed dyslipidaemia, as an adjunct to diet, optionally in combination with lipid-lowering therapies and/or statins Amgen (Repatha)
 

Report Summary

$1,400.00
Fluoxetine  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Fluoxetine - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
$1,400.00
Iloprost  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Iloprost - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Iloprost  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of severe peripheral arterial occlusive disease; Treatment of thromboangiitis obliterans (Buerger's disease) with advanced critical limb ischaemia; Treatment of Raynaud's phenomenon; Treatment of pulmonary hypertension Bayer (Ventavis); Actelion (Ventavis)
 

Report Summary

$1,400.00
Insulin Aspart  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Insulin Aspart - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Insulin Aspart  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of diabetes mellitus optionally in combination with an intermediate-acting or long-acting insulin Novo Nordisk (NovoRapid, Novolog, NovoMix)
 

Report Summary

$1,400.00
Insulin Aspart, Insulin Degludec  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Insulin Aspart, Insulin Degludec - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Insulin Aspart, Insulin Degludec  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of diabetes mellitus Novo Nordisk (Ryzodeg)
 

Report Summary

$1,400.00
Insulin Degludec  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Insulin Degludec - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Insulin Degludec  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of diabetes mellitus Novo Nordisk (Tresiba)
 

Report Summary

$1,400.00
Insulin Lispro  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Insulin Lispro - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Insulin Lispro  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of diabetes mellitus optionally in combination with a longer-acting insulin for type 1 diabetes or in a combination therapy with a sulfonylurea agent for type 2 diabetes Eli Lilly (Humalog, Liprolog)
 

Report Summary

$1,400.00
Lumacaftor, Ivacaftor  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Lumacaftor, Ivacaftor - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Lumacaftor, Ivacaftor  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of cystic fibrosis in patients who are homozygous for F508del mutation in the CFTR gene Vertex Pharm (Orkambi)
 

Report Summary

$1,400.00
Phentermine, Topiramate  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Phentermine, Topiramate - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Phentermine, Topiramate  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management Vivus (Qsymia, Qsiva)
 

Report Summary

$1,400.00
Raxibacumab  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Raxibacumab - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Raxibacumab  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of inhalational anthrax in combination with antibacterial drugs Human Genome Sci (Raxibacumab)
 

Report Summary

$1,400.00
Safinamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Safinamide - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Safinamide  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Treatment of idiopathic Parkinson's disease (PD) as an adjunct to a stable dose of Levodopa alone or in combination with other PD drugs in mid to late-stage fluctuating patients Zambon (Xadago)
 

Report Summary

$1,400.00
Simvastatin, Sitagliptin  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Simvastatin, Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
$1,400.00
Varenicline  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Varenicline - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries)

Date Published: Oct 12 2015
Varenicline  - Patent, Extension and Data Exclusivity Expiry Snapshot (51 countries) Smoking cessation treatment Pfizer (Champix, Chantix)
 

Report Summary

$1,400.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data